Centiva Capital, LP Neurocrine Biosciences Inc Transaction History
Centiva Capital, LP
- $3.13 Billion
- Q1 2025
A detailed history of Centiva Capital, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Centiva Capital, LP holds 9,500 shares of NBIX stock, worth $1.15 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
9,500Holding current value
$1.15 Million% of portfolio
0.03%Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
652Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.72 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.2 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$670 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$588 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$323 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...